(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.81%) $83.17
(1.04%) $1.943
(-0.35%) $2 339.10
(-0.05%) $27.52
(0.62%) $927.80
(-0.24%) $0.932
(-0.23%) $11.00
(-0.30%) $0.798
(0.25%) $92.11
Live Chart Being Loaded With Signals
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders...
Stats | |
---|---|
本日の出来高 | 261 676 |
平均出来高 | 261 312 |
時価総額 | 66.40M |
EPS | $-0.290 ( 2024-04-02 ) |
次の収益日 | ( $-0.280 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.230 |
ATR14 | $0.00500 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Sandercock Colin | Buy | 175 000 | Stock Option (right to buy) |
2024-03-06 | Suri Anish | Buy | 300 000 | Stock Option (right to buy) |
2024-03-06 | Millar Kerri-ann | Buy | 250 000 | Stock Option (right to buy) |
2024-03-06 | Passeri Daniel R | Buy | 400 000 | Stock Option (right to buy) |
2024-03-06 | Levisetti Matteo | Buy | 260 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
98.01 |
Last 98 transactions |
Buy: 5 498 246 | Sell: 593 660 |
ボリューム 相関
Cue Biopharma Inc 相関
10 最も正の相関 | |
---|---|
NLTX | 0.886 |
RPHM | 0.872 |
RNAZ | 0.843 |
SGTX | 0.843 |
ACLX | 0.842 |
ADMP | 0.842 |
NISN | 0.834 |
SDIG | 0.833 |
RMRM | 0.832 |
VCXA | 0.828 |
10 最も負の相関 | |
---|---|
TCBS | -0.877 |
CDW | -0.875 |
MYNZ | -0.87 |
RGP | -0.865 |
RBBN | -0.863 |
PTSI | -0.862 |
CASS | -0.858 |
HOFT | -0.858 |
LSAK | -0.846 |
FFBW | -0.844 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cue Biopharma Inc 相関 - 通貨/商品
Cue Biopharma Inc 財務諸表
Annual | 2023 |
収益: | $5.49M |
総利益: | $2.05M (37.41 %) |
EPS: | $-1.110 |
FY | 2023 |
収益: | $5.49M |
総利益: | $2.05M (37.41 %) |
EPS: | $-1.110 |
FY | 2022 |
収益: | $1.25M |
総利益: | $-560 828 (-45.04 %) |
EPS: | $-1.480 |
FY | 2021 |
収益: | $14.94M |
総利益: | $14.94M (100.00 %) |
EPS: | $-1.410 |
Financial Reports:
No articles found.
Cue Biopharma Inc
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。